Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation.

Authors

Dimpi Patel, Loyola University of Chicago, Stritch School of Medicine, Maywood, IL, United States
Amir Darki, Department of Cardiology, Loyola University Medical Center, Maywood, IL, United States
Debra Hoppensteadt, Hemostasis and Thrombosis Laboratories, Center of Translational Research and Education, Maywood, IL, United States
Iman Darwish, Hemostasis and Thrombosis Laboratories, Center of Translational Research and Education, Maywood, IL, United States
Mushabbar Syed, Department of Cardiology, Loyola University Medical Center, Maywood, IL, United States
Yevgeniy Brailovsky, Department of Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA, United StatesFollow
Jawed Fareed, Hemostasis and Thrombosis Laboratories, Center of Translational Research and Education, Maywood, IL, United States

Document Type

Article

Publication Date

5-20-2021

Comments

This article is the author's final published version in Clinical and Applied Thrombosis/Hemostasis, Volume 27, May 2021.

The published version is available at https://doi.org/10.1177/10760296211014964.

Copyright © The Author(s) 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Abstract

Pulmonary embolism (PE) patients have an increased prevalence and incidence of atrial fibrillation (AF). Because comorbid AF increases risk of morbidity and mortality, we sought to investigate the role of thrombo-inflammatory biomarkers in risk stratifying patients who experience an acute PE episode. Study participants were enrolled from a Pulmonary Embolism Response Team (PERT) registry between March 2016 and March 2019 at Loyola University Medical Center and Gottlieb Memorial Hospital. This cohort was divided into 3 groups: PE patients with a prior diagnosis of AF (n = 8), PE patients with a subsequent diagnosis of AF (n = 11), and PE patients who do not develop AF (n = 71). D-dimer, CRP, PAI-1, TAFIa, FXIIIa, A2A, MP, and TFPI were profiled using the ELISA method. All biomarkers were significantly different between controls and PE patients (P < 0.05). Furthermore, TFPI was significantly elevated in PE patients who subsequently developed AF compared to PE patients who did not develop AF (157.7 ± 19.0 ng/mL vs. 129.0 ± 9.3 ng/mL, P = 0.0386). This study suggests that thrombo-inflammatory biomarkers may be helpful in indicating an acute PE episode. Also, elevated TFPI levels may be associated with an increased risk of developing AF after a PE.

Recommended Citation

Patel, Dimpi; Darki, Amir; Hoppensteadt, Debra; Darwish, Iman; Syed, Mushabbar; Brailovsky, Yevgeniy; and Fareed, Jawed, "Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation." (2021). Division of Cardiology Faculty Papers. Paper 82.
https://jdc.jefferson.edu/cardiologyfp/82

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Language

English

PubMed ID

34013785